TOVALT™ ODT
(zolpidem tartrate)
Orally Disintegrating Tablets

Rx Only

DESCRIPTION

TOVALT™ ODT (zolpidem tartrate) Orally Disintegrating Tablets is a non-benzodiazepine hypnotic of the imidazopyridine class and is available in 5 mg and 10 mg tablet strengths for oral administration.

Chemically, zolpidem is N,N,6-trimethyl-2-p-tolyl-imidazo[1,2-a]pyridine-3-acetamide L-( + )-tartrate (2:1). It has the following structure:

Zolpidem tartrate is a white to off-white crystalline powder that is sparingly soluble in water, alcohol, and propylene glycol. It has a molecular weight of 764.88.

Each TOVALT ODT includes the following inactive ingredients: Acesulfame Potassium, Glyceril Monostearate, Hypromellose, Stearoyl Macrogolglycerides Polyacrylate Dispersion (30%), Talc, Mannitol, Microcrystalline Cellulose, Low Substituted Hydroxypropyl Cellulose, Crospovidone, Sodium Stearyl Fumarate, Silicon Dioxide, Monoammonium Glycyrrhizinate, Natural Intense Peppermint Flavour, FD&C Blue #2 (for 10mg only).

CLINICAL PHARMACOLOGY

Pharmacodynamics
Subunit modulation of the GABA_A receptor chloride channel macromolecular complex is hypothesized to be responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant
drug properties. The major modulatory site of the $\text{GABA}_A$ receptor complex is located on its alpha ($\alpha$) subunit and is referred to as the benzodiazepine (BZ) or omega ($\omega$) receptor. At least three subtypes of the ($\omega$) receptor have been identified. While zolpidem is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which nonselectively bind to and activate all omega receptor subtypes, zolpidem in vitro binds the ($\omega_1$) receptor preferentially with a high affinity ratio of the $\alpha_1 / \alpha_5$ subunits. The ($\omega_1$) receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus. This selective binding of zolpidem on the ($\omega_1$) receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses.

**Pharmacokinetics**

**TOVALT ODT** (zolpidem tartrate) Orally Disintegrating Tablets are bioequivalent to Ambien® tablets.

*Absorption:* Zolpidem is absorbed from the gastrointestinal tract. Following a single 10 mg dose of **TOVALT ODT** in 35 healthy volunteers under fasting conditions, a mean zolpidem $C_{\text{max}}$ of 101.68 ± 32.68 ng/mL was attained at about 1.75 hours. The bioavailability of **TOVALT ODT** relative to the conventional immediate-release formulation is 103%. The pharmacokinetics of zolpidem are linear in the 5 – 10 mg dose range.

*Food Effect:* The pharmacokinetics of zolpidem after concomitant food intake were similar between **TOVALT ODT** and Ambien tablets. Since food decreases AUC and $C_{\text{max}}$ of zolpidem and delays time to peak zolpidem concentrations (by 60%), for faster sleep onset, **TOVALT ODT** should not be administered with or immediately after a meal.

**TOVALT ODT** can be administered with or without water.

*Distribution:* Total protein binding of zolpidem is 92.5 ± 0.1% and remains constant independent of concentration between 40 and 790 ng/mL.

*Metabolism and Excretion:* The mean zolpidem elimination half-life is approximately 3.5 hours, following night time dosing. Zolpidem is converted to inactive metabolites that are eliminated primarily by renal excretion.
Special Populations:

Elderly: In the elderly, the dose for zolpidem tartrate should be 5 mg (see Precautions and Dosage and Administration). This recommendation is based on several studies in which the mean $C_{\text{max}}$, $T_{1/2}$, and AUC were significantly increased when compared to results in young adults. In one study of eight elderly subjects (>70 years), the means for $C_{\text{max}}$, $T_{1/2}$, and AUC significantly increased by 50% (255 vs 384 ng/mL), 32% (2.2 vs 2.9 hr), and 64% (955 vs 1,562 ng·hr/mL), respectively, as compared to younger adults (20 to 40 years) following a single 20 mg oral zolpidem dose. Zolpidem did not accumulate in elderly subjects following nightly oral dosing of 10 mg for 1 week.

Hepatic Impaired: The pharmacokinetics of zolpidem in eight patients with chronic hepatic insufficiency were compared to results in healthy subjects. Following a single 20 mg oral zolpidem dose, mean $C_{\text{max}}$ and AUC were found to be two times (250 vs 499 ng/mL) and five times (788 vs 4,203 ng·hr/mL) higher, respectively, in hepatically compromised patients. $T_{\text{max}}$ did not change. The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normals of 2.2 hr (range: 1.6 to 2.4 hr). Dosing should be modified accordingly in patients with hepatic insufficiency (see Precautions and Dosage and Administration).

Renal Impaired: The pharmacokinetics of zolpidem tartrate were studied in 11 patients with end-stage renal failure (mean $\text{Cl}_{\text{Cr}} = 6.5 \pm 1.5 \text{ mL/min}$) undergoing hemodialysis three times a week, who were dosed with zolpidem 10 mg orally each day for 14 or 21 days. No statistically significant differences were observed for $C_{\text{max}}$, $T_{\text{max}}$, half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made. On day 1, $C_{\text{max}}$ was 172±29 ng/mL (range: 46 to 344 ng/mL). After repeated dosing for 14 or 21 days, $C_{\text{max}}$ was 203±32 ng/mL (range: 28 to 316 ng/mL). On day 1, $T_{\text{max}}$ was 1.7±0.3 hr (range: 0.5 to 3.0 hr); after repeated dosing $T_{\text{max}}$ was 0.8±0.2 hr (range: 0.5 to 2.0 hr). This variation is accounted for by noting that last-day serum sampling began 10 hours after the previous dose, rather than after 24 hours. This resulted in residual drug concentration and a shorter period to reach maximal serum concentration. On day 1, $T_{1/2}$ was 2.4±0.4 hr (range: 0.4 to 5.1 hr). After repeated dosing, $T_{1/2}$ was 2.5±0.4 hr (range: 0.7 to 4.2 hr). AUC was 796±159 ng·hr/mL after the first dose and 818±170 ng·hr/mL after repeated dosing. Zolpidem was not hemodialyzable. No accumulation of unchanged drug appeared after 14 or 21 days. Zolpidem pharmacokinetics were not significantly different in renally impaired patients. No dosage adjustment is necessary in patients with compromised renal function. As a general precaution, these patients should be closely monitored.

Pediatric patients: Safety and effectiveness of zolpidem has not been established in pediatric patients. In an 8-week study in pediatric patients (aged 6-17 years) with insomnia associated with attention-deficit/hyperactivity disorder (ADHD), zolpidem did not decrease sleep latency
compared to placebo. Hallucinations were reported in 7.4% of the pediatric patients who received zolpidem; none of the pediatric patients who received placebo reported hallucinations.

**Postulated relationship between elimination rate of hypnotics and their profile of common untoward effects:** The type and duration of hypnotic effects and the profile of unwanted effects during administration of hypnotic drugs may be influenced by the biologic half-life of administered drug and any active metabolites formed. When half-lives are long, drug or metabolites may accumulate during periods of nightly administration and be associated with impairment of cognitive and/or motor performance during waking hours; the possibility of interaction with other psychoactive drugs or alcohol will be enhanced. In contrast, if half-lives, including half-lives of active metabolites, are short, drug and metabolites will be cleared before the next dose is ingested, and carryover effects related to excessive sedation or CNS depression should be minimal or absent. Zolpidem has a short half-life and no active metabolites. During nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of hypnotics may develop. If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug or its active metabolites (i.e., in relationship to the receptor site) may occur at some point in the interval between each night's use. This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of other rapidly eliminated hypnotics, namely, increased wakefulness during the last third of the night, and the appearance of increased signs of daytime anxiety. Increased wakefulness during the last third of the night as measured by polysomnography has not been observed in clinical trials with zolpidem tartrate.

**CONTROLLED TRIALS SUPPORTING SAFETY AND EFFICACY**

*Transient insomnia:* Normal adults experiencing transient insomnia (n=462) during the first night in a sleep laboratory were evaluated in a double-blind, parallel group, single-night trial comparing two doses of zolpidem (7.5 and 10 mg) and placebo. Both zolpidem doses were superior to placebo on objective (polysomnographic) measures of sleep latency, sleep duration, and number of awakenings. Normal elderly adults (mean age 68) experiencing transient insomnia (n=35) during the first two nights in a sleep laboratory were evaluated in a double-blind, crossover, 2-night trial comparing four doses of zolpidem (5, 10, 15 and 20 mg) and placebo. All zolpidem doses were superior to placebo on the two primary PSG parameters (sleep latency and efficiency) and all four subjective outcome measures (sleep duration, sleep latency, number of awakenings, and sleep quality).

*Chronic insomnia:* Zolpidem was evaluated in two controlled studies for the treatment of patients with chronic insomnia (most closely resembling primary insomnia, as defined in
the APA Diagnostic and Statistical Manual of Mental Disorders, DSM-IV™). Adult outpatients with chronic insomnia (n=75) were evaluated in a double-blind, parallel group, 5-week trial comparing two doses of zolpidem tartrate (10 and 15 mg) and placebo. On objective (polysomnographic) measures of sleep latency and sleep efficiency, zolpidem 15 mg was superior to placebo for all 5 weeks; zolpidem 10 mg was superior to placebo on sleep latency for the first 4 weeks and on sleep efficiency for weeks 2 and 4. Zolpidem was comparable to placebo on number of awakenings at both doses studied.

Adult outpatients (n=141) with chronic insomnia were also evaluated in a double-blind, parallel group, 4-week trial comparing two doses of zolpidem (10 and 15 mg) and placebo. Zolpidem 10 mg was superior to placebo on a subjective measure of sleep latency for all 4 weeks, and on subjective measures of total sleep time, number of awakenings, and sleep quality for the first treatment week. Zolpidem 15 mg was superior to placebo on a subjective measure of total sleep latency for the first 3 weeks, on a subjective measure of total sleep time for the first week, and on number of awakenings and sleep quality for the first 2 weeks.

**Next-day residual effects:** Next-day residual effects of zolpidem were evaluated in seven studies involving normal volunteers. In three studies in adults (including one study in a phase advance model of transient insomnia) and in one study in elderly subjects, a small but statistically significant decrease in performance was observed in the Digit Symbol Substitution Test (DSST) when compared to placebo. Studies of zolpidem in non-elderly patients with insomnia did not detect evidence of next-day residual effects using the DSST, the Multiple Sleep Latency Test (MSLT), and patient ratings of alertness.

**Rebound effects:** There was no objective (polysomnographic) evidence of rebound insomnia at recommended doses seen in studies evaluating sleep on the nights following discontinuation of zolpidem tartrate. There was subjective evidence of impaired sleep in the elderly on the first post-treatment night at doses above the recommended elderly dose of 5 mg.

**Memory impairment:** Controlled studies in adults utilizing objective measures of memory yielded no consistent evidence of next-day memory impairment following the administration of zolpidem. However, in one study involving zolpidem doses of 10 and 20 mg, there was a significant decrease in next-morning recall of information presented to subjects during peak drug effect (90 minutes post-dose), i.e., these subjects experienced anterograde amnesia. There was also subjective evidence from adverse event data for anterograde amnesia occurring in association with the administration of zolpidem, predominantly at doses above 10 mg.

**Effects on sleep stages:** In studies that measured the percentage of sleep time spent in each sleep stage, zolpidem has generally been shown to preserve sleep stages. Sleep time
spent in stages 3 and 4 (deep sleep) was found comparable to placebo with only inconsistent, minor changes in REM (paradoxical) sleep at the recommended dose.

**INDICATIONS AND USAGE**

**TOVALT ODT** (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem has been shown to decrease sleep latency for up to 35 days in controlled clinical studies (see Clinical Pharmacology: Controlled trials supporting safety and efficacy). The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.

**CONTRAINDICATIONS**

None known.

**WARNINGS**

Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. **The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.**

Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including zolpidem. Because some of the important adverse effects of zolpidem appear to be dose related (see Precautions and Dosage and Administration), it is important to use the smallest possible effective dose, especially in the elderly.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative-hypnotics. Some of these changes may be characterized by decreased inhibition (e.g., aggressiveness and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Visual and auditory hallucinations have been reported as well as behavioral changes such as bizarre behavior, agitation, and depersonalization.

Complex behaviours such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. These events can occur in sedative-hypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as sleep-driving may occur with **TOVALT ODT**
alone at therapeutic doses, the use of alcohol and other CNS depressants with zolpidem tartrate tablets appears to increase the risk of such behaviors, as does the use of zolpidem tartrate tablets at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of TOVALT ODT should be strongly considered for patients who report a “sleep-driving” episode. Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

Amnesia, anxiety and other neuro-psychiatric symptoms may occur unpredictably. In primarily depressed patients, worsening of depression, including suicidal thinking, has been reported in association with the use of sedative-hypnotics.

It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation.

Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs (see Drug Abuse and Dependence).

TOVALT ODT, like other sedative/hypnotic drugs, has CNS-depressant effects. Due to the rapid onset of action, TOVALT ODT should only be taken immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of TOVALT ODT. Zolpidem showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when TOVALT ODT is administered with such agents because of the potentially additive effects.

Severe anaphylactic and anaphylactoid reactions

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem tartrate tablets. Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis. Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with TOVALT ODT should not be rechallenged with the drug.
PRECAUTIONS

General

Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended TOVALT ODT dosage is 5 mg in such patients (see Dosage and Administration) to decrease the possibility of side effects. These patients should be closely monitored.

Use in patients with concomitant illness: Clinical experience with zolpidem tartrate in patients with concomitant systemic illness is limited. Caution is advisable in using TOVALT ODT in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Although studies did not reveal respiratory depressant effects at hypnotic doses of zolpidem tartrate in normals or in patients with mild to moderate chronic obstructive pulmonary disease (COPD), a reduction in the Total Arousal Index together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90% was observed in patients with mild-to-moderate sleep apnea when treated with zolpidem tartrate (10 mg) when compared to placebo. However, precautions should be observed if TOVALT ODT is prescribed to patients with compromised respiratory function, since sedative/hypnotics have the capacity to depress respiratory drive. Post-marketing reports of respiratory insufficiency, most of which involved patients with pre-existing respiratory impairment, have been received. Data in end-stage renal failure patients repeatedly treated with zolpidem tartrate did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored (see Pharmacokinetics). A study in subjects with hepatic impairment did reveal prolonged elimination in this group; therefore, treatment should be initiated with 5 mg in patients with hepatic compromise, and they should be closely monitored.

Use in depression: As with other sedative/hypnotic drugs, TOVALT ODT should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional over-dosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

Information for patients: Patient information is printed at the end of this insert. To assure safe and effective use of TOVALT ODT, this information and instructions provided in the patient information section should be discussed with patients.
SPECIAL CONCERNS

“Sleep-Driving” and other complex behaviors

There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since “sleep-driving” can be dangerous. This behavior is more likely to occur when TOVALT ODT is taken with alcohol or other central nervous system depressants (see WARNINGS). Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

Patients should be instructed not to remove the tablet from the blister until just prior to dosing; once removed, it cannot be stored.

- To open the blister pack, peel back the foil on the blister. Do not push tablet through the foil. Remove the tablet and place it in the mouth, where it will dissolve in seconds and then be swallowed with the saliva.
- TOVALT ODT may be taken with or without water.
- Do NOT chew, break, or split the tablet.

Laboratory tests: There are no specific laboratory tests recommended.

Drug interactions

CNS-active drugs: Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.

An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated.

A single-dose interaction study with zolpidem 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions. When multiple doses of zolpidem and fluoxetine at steady-state concentrations were evaluated in healthy females, the only significant change
was a 17% increase in the zolpidem half-life. There was no evidence of an additive effect in psychomotor performance.

Following five consecutive nightly doses of zolpidem 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem $C_{\text{max}}$ was significantly higher (43%) and $T_{\text{max}}$ was significantly decreased (53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.

Since the systematic evaluations of zolpidem tartrate in combination with other CNS-active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of zolpidem.

**Drugs that affect drug metabolism via cytochrome P450:** A randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC $0 \rightarrow \infty$ of zolpidem. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance.

A randomized, placebo-controlled, crossover interaction study in eight healthy female volunteers between 5 consecutive daily doses of rifampin (600 mg) and a single dose of zolpidem (20 mg) given 17 hours after the last dose of rifampin showed significant reductions of the AUC (-73%), $C_{\text{max}}$ (-58%), and $T_{1/2}$ (-36%) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem.

**Other drugs:** A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem. Zolpidem had no effect on digoxin kinetics and did not affect prothrombin time when given with warfarin in normal subjects. Zolpidem's sedative/hypnotic effect was reversed by flumazenil; however, no significant alterations in zolpidem pharmacokinetics were found.

**Drug/Laboratory test interactions:** Zolpidem is not known to interfere with commonly employed clinical laboratory tests. In addition, clinical data indicate that zolpidem does not cross-react with benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screens.

**Carcinogenesis, mutagenesis, impairment of fertility**

**Carcinogenesis:** Zolpidem was administered to rats and mice for 2 years at dietary dosages of 4, 18, and 80 mg/kg/day. In mice, these dosages are 26 to 520 times or 2 to 35 times the maximum 10-mg human dose on a mg/kg or mg/m$^2$ basis, respectively. In rats these doses are 43 to 876 times or 6 to 115 times the maximum 10-mg human dose on a mg/kg or mg/m$^2$ basis, respectively. No evidence of carcinogenic potential was observed in mice. Renal liposarcomas were seen in 4/100 rats (3 males, 1 female) receiving 80
mg/kg/day and a renal lipoma was observed in one male rat at the 18 mg/kg/day dose. Incidence rates of lipoma and liposarcoma for zolpidem were comparable to those seen in historical controls and the tumor findings are thought to be a spontaneous occurrence.

**Mutagenesis:** Zolpidem did not have mutagenic activity in several tests including the Ames test, genotoxicity in mouse lymphoma cells in vitro, chromosomal aberrations in cultured human lymphocytes, unscheduled DNA synthesis in rat hepatocytes in vitro, and the micronucleus test in mice.

**Impairment of fertility:** In a rat reproduction study, the high dose (100 mg base/kg) of zolpidem resulted in irregular estrus cycles and prolonged precoital intervals, but there was no effect on male or female fertility after daily oral doses of 4 to 100 mg base/kg or 5 to 130 times the recommended human dose in mg/m². No effects on any other fertility parameters were noted.

**Pregnancy**

**Teratogenic effects:** Pregnancy Category C. Studies to assess the effects of zolpidem on human reproduction and development have not been conducted. Teratology studies were conducted in rats and rabbits. In rats, adverse maternal and fetal effects occurred at 20 and 100 mg base/kg and included dose-related maternal lethargy and ataxia and a dose-related trend to incomplete ossification of fetal skull bones. Decreased body weight and decreased rat pup survival were also seen. There were no teratogenic effects after zolpidem administration. The no-effect dose for maternal or fetal toxicity was 4 mg base/kg or 5 times the maximum human dose on a mg/m² basis.

In rabbits, dose-related maternal sedation and decreased weight gain occurred at all doses tested. At the high dose, 16 mg base/kg, there was an increase in postimplantation fetal loss and underossification of sternebrae in viable fetuses. There were no frank teratogenic effects. The no-effect dose for fetal toxicity was 4 mg base/kg or 9-10 times the maximum human dose on a mg/m² basis.

Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nonteratogenic effects:** Studies to assess the effects on children whose mothers took zolpidem during pregnancy have not been conducted. However, children born of mothers taking sedative/hypnotic drugs may be at some risk for withdrawal symptoms from the drug during the postnatal period. In addition, neonatal flaccidity has been reported in infants born of mothers who received sedative/hypnotic drugs during pregnancy.

**Labor and delivery:** TOVALT ODT (zolpidem tartrate) has no established use in labor and delivery.

**Nursing mothers:** Studies in lactating mothers indicate that the half-life of zolpidem is similar to that in young normal volunteers (2.6 ± 0.3 hr). Between 0.004 and 0.019% of
the total administered dose is excreted into milk, but the effect of zolpidem on the infant is unknown.
In addition, in a rat study, zolpidem inhibited the secretion of milk. The no-effect dose was 4 mg base/kg or 6 times the recommended human dose in mg/m². The use of TOVALT ODT in nursing mothers is not recommended.

**Pediatric use:** Safety and effectiveness in pediatric patients below the age of 18 have not been established.
In an 8-week controlled study, 201 pediatric patients (aged 6-17 years) with insomnia associated with attention-deficit/hyperactivity disorder were treated with an oral solution of zolpidem or placebo. Zolpidem did not significantly decrease latency to persistent sleep, compared to placebo, as measured by polysomnography after 4 weeks of treatment. Psychiatric and nervous system disorders comprised the most frequent (> 5%) treatment emergent adverse events observed with zolpidem versus placebo and included dizziness (23.5% vs. 1.5%), headache (12.5% vs. 9.2%), and hallucinations (7.4% vs. 0%). Ten patients on zolpidem (7.4%) discontinued treatment due to an adverse event.

**Geriatric use:** A total of 154 patients in U.S. controlled clinical trials and 897 patients in non-U.S. clinical trials who received zolpidem were ≥ 60 years of age. For a pool of U.S. patients receiving zolpidem at doses of ≤ 10 mg or placebo, there were three adverse events occurring at an incidence of at least 3% for zolpidem and for which the zolpidem incidence was at least twice the placebo incidence (i.e., they could be considered drug related).

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Zolpidem</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>3%</td>
<td>0%</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>5%</td>
<td>2%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3%</td>
<td>1%</td>
</tr>
</tbody>
</table>

A total of 30/1,959 (1.5%) non-U.S. patients receiving zolpidem reported falls, including 28/30 (93%) who were ≥ 70 years of age. Of these 28 patients, 23 (82%) were receiving zolpidem doses >10 mg. A total of 24/1,959 (1.2%) non-U.S. patients receiving zolpidem reported confusion, including 18/24 (75%) who were ≥ 70 years of age. Of these 18 patients, 14 (78%) were receiving zolpidem doses >10 mg.

**ADVERSE REACTIONS**

*Associated with discontinuation of treatment:* Approximately 4% of 1,701 patients who received zolpidem at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials
discontinued treatment because of an adverse clinical event. Events most commonly associated with discontinuation from U.S. trials were daytime drowsiness (0.5%), dizziness (0.4%), headache (0.5%), nausea (0.6%), and vomiting (0.5%). Approximately 4% of 1,959 patients who received zolpidem at all doses (1 to 50 mg) in similar foreign trials discontinued treatment because of an adverse event. Events most commonly associated with discontinuation from these trials were daytime drowsiness (1.1%), dizziness/vertigo (0.8%), amnesia (0.5%), nausea (0.5%), headache (0.4%), and falls (0.4%). Data from a clinical study in which selective serotonin reuptake inhibitor- (SSRI) treated patients were given zolpidem revealed that four of the seven discontinuations during double-blind treatment with zolpidem (n=95) were associated with impaired concentration, continuing or aggravated depression, and manic reaction; one patient treated with placebo (n=97) was discontinued after an attempted suicide.

**Incidence in controlled clinical trials**

**Most commonly observed adverse events in controlled trials:** During short-term treatment (up to 10 nights) with zolpidem tartrate at doses up to 10 mg, the most commonly observed adverse events associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were drowsiness (reported by 2% of zolpidem patients), dizziness (1%), and diarrhea (1%). During longer-term treatment (28 to 35 nights) with zolpidem at doses up to 10 mg, the most commonly observed adverse events associated with the use of zolpidem and seen at statistically significant differences from placebo-treated patients were dizziness (5%) and drugged feelings (3%).

**Adverse events observed at an incidence of \( \geq 1\% \) in controlled trials:** The following tables enumerate treatment-emergent adverse event frequencies that were observed at an incidence equal to 1% or greater and at a greater incidence than placebo among patients with insomnia who received zolpidem tartrate in U.S. placebo-controlled trials. Events reported by investigators were classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms for the purpose of establishing event frequencies. The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice, in which patient characteristics and other factors differ from those that prevailed in these clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigators involving related drug products and uses, since each group of drug trials is conducted under a different set of conditions. However, the cited figures provide the physician with a basis for estimating the relative contribution of drug and nondrug factors to the incidence of side effects in the population studied.
The following table was derived from a pool of 11 placebo-controlled short-term U.S. efficacy trials involving zolpidem in doses ranging from 1.25 to 20 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use.

<table>
<thead>
<tr>
<th>Body System/Adverse Event *</th>
<th>Zolpidem (≤ 10 mg) (N=685)</th>
<th>Placebo (N=473)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autonomic Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Allergy</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Back pain</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

The following table was derived from a pool of three placebo-controlled long-term efficacy trials involving zolpidem tartrate. These trials involved patients with chronic insomnia who were treated for 28 to 35 nights with zolpidem at doses of 5, 10, or 15 mg. The table is limited to data from doses up to and including 10 mg, the highest dose recommended for use. The table includes only adverse events occurring at an incidence of at least 1% for zolpidem patients.

<table>
<thead>
<tr>
<th>Body System/Adverse Event *</th>
<th>Zolpidem (≤ 10 mg) (N=152)</th>
<th>Placebo (N=161)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central and Peripheral Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Gastrointestinal System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1</td>
<td>-</td>
</tr>
</tbody>
</table>

*Events reported by at least 1% of zolpidem patients are included.
<table>
<thead>
<tr>
<th>System</th>
<th>Events</th>
<th>Frequency</th>
<th>Dose Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza-like symptoms</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Chest pain</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular System</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpitation</td>
<td>2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Central and Peripheral Nervous System</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drowsiness</td>
<td>8</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Dizziness</td>
<td>5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Lethargy</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Drugged feeling</td>
<td>3</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Lightheadedness</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Abnormal dreams</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Amnesia</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Sleep disorder</td>
<td>1</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal System</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Respiratory System</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinusitis</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Skin and Appendages</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

*Events reported by at least 1% of patients treated with zolpidem.

**Dose relationship for adverse events:** There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse events associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse events.

**Adverse event incidence across the entire preapproval database:** Zolpidem tartrate was administered to 3,660 subjects in clinical trials throughout the U.S., Canada, and Europe. Treatment-emergent adverse events associated with clinical trial participation were recorded by clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals experiencing treatment-emergent adverse events, similar types of untoward events were grouped into a smaller number of
standardized event categories and classified utilizing a modified World Health Organization (WHO) dictionary of preferred terms. The frequencies presented, therefore, represent the proportions of the 3,660 individuals exposed to zolpidem, at all doses, who experienced an event of the type cited on at least one occasion while receiving zolpidem. All reported treatment-emergent adverse events are included, except those already listed in the table above of adverse events in placebo-controlled studies, those coding terms that are so general as to be uninformative, and those events where a drug cause was remote. It is important to emphasize that, although the events reported did occur during treatment with zolpidem tartrate, they were not necessarily caused by it.

Adverse events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.

**Autonomic nervous system:** Infrequent: increased sweating, pallor, postural hypotension, syncope. Rare: abnormal accommodation, altered saliva, flushing, glaucoma, hypotension, impotence, increased saliva, tenesmus.

**Body as a whole:** Frequent: asthenia. Infrequent: edema, falling, fever, malaise, trauma. Rare: allergic reaction, allergy aggravated, abdominal body sensation, anaphylactic shock, face edema, hot flashes, increased ESR, pain, restless legs, rigors, tolerance increased, weight decrease.

**Cardiovascular system:** Infrequent: cerebrovascular disorder, hypertension, tachycardia. Rare: angina pectoris, arrhythmia, arteritis, circulatory failure, extrasystoles, hypertension aggravated, myocardial infarction, phlebitis, pulmonary embolism, pulmonary edema, varicose veins, ventricular tachycardia.

**Central and peripheral nervous system:** Frequent: ataxia, confusion, euphoria, insomnia, vertigo. Infrequent: agitation, decreased cognition, detached, difficulty concentrating, dysarthria, emotional lability, hallucination, hypoesthesia, illusion, leg cramps, migraine, paresthesia, sleeping (after daytime dosing), speech disorder, stupor, tremor. Rare: abnormal gait, abnormal thinking, aggressive reaction, apathy, appetite increased, decreased libido, delusion, dementia, depersonalization, dysphasia, feeling strange, hypokinesia, hypotonia, hysteria, intoxicated feeling, manic reaction, neuralgia, neuritis, neuropathy, neurosis, panic attacks, paresis, personality disorder, somnambulism, suicide attempts, tetany, yawning.

**Gastrointestinal system:** Frequent: hiccup. Infrequent: constipation, dysphagia, flatulence, gastroenteritis. Rare: enteritis, eructation, esophagospasm, gastritis, hemorrhoids, intestinal obstruction, rectal hemorrhage, tooth caries.

**Hematologic and lymphatic system:** Rare: anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy, macrocytic anemia, purpura, thrombosis.
**Immunologic system:** Rare: abscess, herpes simplex, herpes zoster, otitis externa, otitis media.

**Liver and biliary system:** Infrequent: abnormal hepatic function, increased SGPT. Rare: bilirubinemia, increased SGOT.

**Metabolic and nutritional:** Infrequent: hyperglycemia, thirst. Rare: gout, hypercholesteremia, hyperlipidemia, increased alkaline phosphatase, increased BUN, periorbital edema.

**Musculoskeletal system:** Infrequent: arthritis. Rare: arthrosis, muscle weakness, sciatica, tendonitis.

**Reproductive system:** Infrequent: menstrual disorder, vaginitis. Rare: breast fibroadenosis, breast neoplasm, breast pain.

**Respiratory system:** Infrequent: bronchitis, coughing, dyspnea. Rare: bronchospasm, epistaxis, hypoxia, laryngitis, pneumonia.

**Skin and appendages:** Infrequent: pruritus. Rare: acne, bullous eruption, dermatitis, furunculosis, injection-site inflammation, photosensitivity reaction, urticaria.

**Special senses:** Frequent: diplopia, vision abnormal. Infrequent: eye irritation, eye pain, scleritis, taste perversion, tinnitus. Rare: conjunctivitis, corneal ulceration, lacrimation abnormal, parosmia, photopsia.

**Urogenital system:** Infrequent: cystitis, urinary incontinence. Rare: acute renal failure, dysuria, micturition frequency, nocturia, polyuria, pyelonephritis, renal pain, urinary retention.

**DRUG ABUSE AND DEPENDENCE**

**Controlled substance:** Zolpidem tartrate is classified as a Schedule IV controlled substance by federal regulation.

**Abuse and dependence:** Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time. Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects. Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use,
compulsive use, continued use despite harm, and craving. Drug addiction is a treatable
disease, utilizing a multidisciplinary approach, but relapse is common.
Studies of abuse potential in former drug abusers found that the effects of single doses of
zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while
zolpidem tartrate 10 mg was difficult to distinguish from placebo.
Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt
discontinuation. These reported symptoms range from mild dysphoria and insomnia to a
withdrawal syndrome that may include abdominal and muscle cramps, vomiting,
sweating, tremors, and convulsions. The U.S. clinical trial experience from zolpidem
does not reveal any clear evidence for withdrawal syndrome. Nevertheless, the following
adverse events included in DSM-III-R criteria for uncomplicated sedative/hypnotic
withdrawal were reported during U.S. clinical trials following placebo substitution
occurring within 48 hours following last zolpidem treatment: fatigue, nausea, flushing,
lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness,
and abdominal discomfort. These reported adverse events occurred at an incidence of 1% or
less. However, available data cannot provide a reliable estimate of the incidence, if
any, of dependence during treatment at recommended doses. Rare postmarketing reports
of abuse, dependence and withdrawal have been received.
Because persons with a history of addiction to, or abuse of, drugs or alcohol are at
increased risk of habituation and dependence, they should be under careful surveillance
when receiving zolpidem or any other hypnotic.

OVERDOSAGE

**Signs and symptoms:** In European postmarketing reports of overdose with zolpidem
alone, impairment of consciousness has ranged from somnolence to light coma. There
was one case each of cardiovascular and respiratory compromise. Individuals have fully
recovered from zolpidem tartrate overdoses up to 400 mg (40 times the maximum
recommended dose). Overdose cases involving multiple CNS-depressant agents,
including zolpidem, have resulted in more severe symptomatology, including fatal
outcomes.

**Recommended treatment:** General symptomatic and supportive measures should be
used along with immediate gastric lavage where appropriate. Intravenous fluids should be
administered as needed. Flumazenil may be useful. As in all cases of drug overdose,
respiration, pulse, blood pressure, and other appropriate signs should be monitored and
general supportive measures employed. Hypotension and CNS depression should be
monitored and treated by appropriate medical intervention. Sedating drugs should be
withheld following zolpidem overdosage, even if excitation occurs. The value of dialysis
in the treatment of overdosage has not been determined, although hemodialysis studies in
patients with renal failure receiving therapeutic doses have demonstrated that zolpidem is not dialyzable.  

**Poison control center:** As with the management of all overdosage, the possibility of multiple drug ingestion should be considered. The physician may wish to consider contacting a poison control center for up-to-date information on the management of hypnotic drug product overdosage.

**DOSAGE AND ADMINISTRATION**

The dose of **TOVALT ODT** should be individualized. The recommended dose for adults is 10 mg immediately before bedtime. Downward dosage adjustment may be necessary when **TOVALT ODT** is administered with agents having known CNS-depressant effects because of the potentially additive effects. Elderly or debilitated patients may be especially sensitive to the effects of **TOVALT ODT** (zolpidem tartrate). Patients with hepatic insufficiency do not clear the drug as rapidly as normals. An initial 5 mg dose is recommended in these patients (see Precautions ).

The total **TOVALT ODT** dose should not exceed 10 mg. Place the **TOVALT ODT** tablet in the mouth where it disintegrates in seconds and can then be swallowed. The tablet may be taken with or without water. Do NOT chew, break, or split the tablet. **TOVALT ODT** should not be administered with or immediately after a meal.

**HOW SUPPLIED**

**TOVALT ODT** (zolpidem tartrate) is supplied as orally disintegrating tablets in two dosage strengths:

5 mg tablets are round, white tablets with off-white speckles with a dimple on both sides and debossed with ‘ZT’ on one side and ‘5’ on the other, and supplied in cartons of 28 tablets (4 cards of 7 single dose units) in child-resistant blister packs. 
NDC 64455-158-28

10 mg tablets are round, blue tablets with white speckles with a dimple on both sides and debossed with ‘ZT’ on one side and ‘10’ on the other, and supplied in cartons of 28 tablets (4 cards of 7 single dose units) in child-resistant blister packs. 
NDC 64455-159-28

Store at controlled room temperature 20°- 25° C (68°-77°F).
INFORMATION FOR PATIENTS TAKING TOVALT ODT

Your doctor has prescribed TOVALT ODT to help you sleep. The following information is intended to guide you in the safe use of this medicine. It is not meant to take the place of your doctor's instructions. If you have any questions about TOVALT ODT tablets be sure to ask your doctor or pharmacist.

TOVALT ODT is used to treat different types of sleep problems, such as:

- trouble falling asleep
- waking up too early in the morning
- waking up often during the night

Some people may have more than one of these problems.

TOVALT ODT belongs to a group of medicines known as the "sedative/hypnotics," or simply, sleep medicines. There are many different sleep medicines available to help people sleep better. Sleep problems are usually temporary, requiring treatment for only a short time, usually 1 or 2 days up to 1 or 2 weeks. Some people have chronic sleep problems that may require more prolonged use of sleep medicine. However, you should not use these medicines for long periods without talking with your doctor about the risks and benefits of prolonged use.
SIDE EFFECTS

**Most common side effects:** All medicines have side effects. Most common side effects of sleep medicines include:

- drowsiness
- dizziness
- lightheadedness
- difficulty with coordination

You may find that these medicines make you sleepy during the day. How drowsy you feel depends upon how your body reacts to the medicine, which sleep medicine you are taking, and how large a dose your doctor has prescribed. Daytime drowsiness is best avoided by taking the lowest dose possible that will still help you sleep at night. Your doctor will work with you to find the dose of **TOVALT ODT** that is best for you.

To manage these side effects while you are taking this medicine:

- When you first start taking **TOVALT ODT** or any other sleep medicine until you know whether the medicine will still have some carryover effect in you the next day, use extreme care while doing anything that requires complete alertness, such as driving a car, operating machinery, or piloting an aircraft.
- NEVER drink alcohol while you are being treated with **TOVALT ODT** or any sleep medicine. Alcohol can increase the side effects of **TOVALT ODT** or any other sleep medicine.
- Do not take any other medicines without asking your doctor first. This includes medicines you can buy without a prescription. Some medicines can cause drowsiness and are best avoided while taking **TOVALT ODT**.

Always take the exact dose of **TOVALT ODT** prescribed by your doctor. Never change your dose without talking to your doctor first.

SPECIAL CONCERNS

There are some special problems that may occur while taking sleep medicines.

“Sleep-Driving” and other complex behaviors

There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since
“sleep-driving” can be dangerous. This behavior is more likely to occur when TOVALT ODT is taken with alcohol or other central nervous system depressants (see WARNINGS). Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

**Memory problems:** Sleep medicines may cause a special type of memory loss or "amnesia." When this occurs, a person may not remember what has happened for several hours after taking the medicine. This is usually not a problem since most people fall asleep after taking the medicine.

Memory loss can be a problem, however, when sleep medicines are taken while traveling, such as during an airplane flight and the person wakes up before the effect of the medicine is gone. This has been called "traveler's amnesia."

Memory problems are not common while taking TOVALT ODT. In most instances memory problems can be avoided if you take TOVALT ODT only when you are able to get a full night's sleep (7 to 8 hours) before you need to be active again. Be sure to talk to your doctor if you think you are having memory problems.

**Tolerance:** When sleep medicines are used every night for more than a few weeks, they may lose their effectiveness to help you sleep. This is known as "tolerance." Sleep medicines should, in most cases, be used only for short periods of time, such as 1 or 2 days and generally no longer than 1 or 2 weeks. If your sleep problems continue, consult your doctor, who will determine whether other measures are needed to overcome your sleep problems.

**Dependence:** Sleep medicines can cause dependence, especially when these medicines are used regularly for longer than a few weeks or at high doses. Some people develop a need to continue taking their medicines. This is known as dependence or "addiction." When people develop dependence, they may have difficulty stopping the sleep medicine. If the medicine is suddenly stopped, the body is not able to function normally and unpleasant symptoms (see **Withdrawal**) may occur. They may find they have to keep taking the medicine either at the prescribed dose or at increasing doses just to avoid withdrawal symptoms.

All people taking sleep medicines have some risk of becoming dependent on the medicine. However, people who have been dependent on alcohol or other drugs in the past may have a higher chance of becoming addicted to sleep medicines. This possibility must be considered before using these medicines for more than a few weeks. If you have been addicted to alcohol or drugs in the past, it is important to tell your doctor before starting TOVALT ODT or any sleep medicine.
Withdrawal: Withdrawal symptoms may occur when sleep medicines are stopped suddenly after being used daily for a long time. In some cases, these symptoms can occur even if the medicine has been used for only a week or two. In mild cases, withdrawal symptoms may include unpleasant feelings. In more severe cases, abdominal and muscle cramps, vomiting, sweating, shakiness, and rarely, seizures may occur. These more severe withdrawal symptoms are very uncommon.

Another problem that may occur when sleep medicines are stopped is known as "rebound insomnia." This means that a person may have more trouble sleeping the first few nights after the medicine is stopped than before starting the medicine. If you should experience rebound insomnia, do not get discouraged. This problem usually goes away on its own after 1 or 2 nights.

If you have been taking TOVALT ODT or any other sleep medicine for more than 1 or 2 weeks, do not stop taking it on your own. Always follow your doctor's directions.

Changes in behavior and thinking: Some people using sleep medicines have experienced unusual changes in their thinking and/or behavior. These effects are not common. However, they have included:

- more outgoing or aggressive behavior than normal
- loss of personal identity
- confusion
- strange behavior
- agitation
- hallucinations
- worsening of depression
- suicidal thoughts

How often these effects occur depends on several factors, such as a person's general health, the use of other medicines, and which sleep medicine is being used. Clinical experience with this drug suggests that it is uncommonly associated with these behavior changes.

It is also important to realize that it is rarely clear whether these behavior changes are caused by the medicine, an illness, or occur on their own. In fact, sleep problems that do not improve may be due to illnesses that were present before the medicine was used. If you or your family notice any changes in your behavior, or if you have any unusual or disturbing thoughts, call your doctor immediately.

Pregnancy: Sleep medicines may cause sedation of the unborn baby when used during the last weeks of pregnancy.
Be sure to tell your doctor if you are pregnant, if you are planning to become pregnant, or if you become pregnant while taking TOVALT ODT.

**Children:** Zolpidem tartrate tablets have not been shown to help children fall asleep. Hallucinations, headache and dizziness have all been reported as side effects in children who were given zolpidem tartrate.

**SAFE USE OF SLEEPING MEDICINES**

Patients should be instructed not to remove the tablet from the blister until just prior to dosing; once removed, it cannot be stored.

To open the blister pack, peel back the foil on the blister. Do not push tablet through the foil.

Remove the tablet and place it in the mouth, where it will dissolve in seconds and then be swallowed with the saliva.

**TOVALT ODT** may be taken with or without water.

Do NOT chew, break, or split the tablet.

**TOVALT ODT** should not be administered with or immediately after a meal.

To ensure the safe and effective use of **TOVALT ODT** or any other sleep medicine, you should observe the following cautions:

1. **TOVALT ODT** is a prescription medicine and should be used ONLY as directed by your doctor. Follow your doctor's instructions about how to take, when to take, and how long to take **TOVALT ODT**.
2. Never use **TOVALT ODT** or any other sleep medicine for longer than directed by your doctor.
3. If you develop an allergic reaction such as rash, hives, shortness of breath or swelling of your throat or tongue when using **TOVALT ODT**, discontinue **TOVALT ODT** immediately and contact your doctor.
4. If you notice any unusual and/or disturbing thoughts or behavior during treatment with **TOVALT ODT** or any other sleep medicine, contact your doctor.
5. Tell your doctor about any medicines you may be taking, including medicines you may buy without a prescription. You should also tell your doctor if you drink alcohol. DO NOT use alcohol while taking **TOVALT ODT** or any other sleep medicine.
6. Do not take **TOVALT ODT** unless you are able to get a full night's sleep before you must be active again. For example, **TOVALT ODT** should not be taken on an overnight airplane flight of less than 7 to 8 hours since "traveler's amnesia" may occur.
7. Do not increase the prescribed dose of TOVALT ODT or any other sleep medicine unless instructed by your doctor.

8. When you first start taking TOVALT ODT or any other sleep medicine until you know whether the medicine will still have some carryover effect in you the next day, use extreme care while doing anything that requires complete alertness, such as driving a car, operating machinery, or piloting an aircraft.

9. Be aware that you may have more sleeping problems the first night or two after stopping TOVALT ODT or any other sleep medicine.

10. Be sure to tell your doctor if you are pregnant, if you are planning to become pregnant, or if you become pregnant while taking TOVALT ODT.

11. As with all prescription medicines, never share TOVALT ODT or any other sleep medicine with anyone else. Always store TOVALT ODT or any other sleep medicine in the original container out of reach of children.

12. TOVALT ODT works very quickly. You should only take TOVALT ODT right before going to bed and are ready to go to sleep.